VONVENDI is now approved for perioperative management of bleeding in adults with VWD VONVENDI is now approved for perioperative management of bleeding in adults with VWD

Now

approved for

use in surgery1

Register
to learn more>

VONVENDI®
[von Willebrand factor (Recombinant)]

Is in your corner

A recombinant von Willebrand factor with an option to dose independently of Recombinant Factor VIII

For each bleeding episode, administer the first dose of VONVENDI with an approved recombinant (non-von Willebrand factor-containing) factor VIII (rFVIII) if FVIII baseline levels are <40% or are unknown. VONVENDI can be administered without rFVIII in some patients if FVIII levels are ≥40% normal activity (0.4 IU/mL) or if an urgent increase is not needed.1

Comprehensive dosing information can be found in the VONVENDI full Prescribing Information.

Introduction to von Willebrand factor function in hemostasis

Understanding VWD

Get an introduction to VWF function in hemostasis

See what VONVENDI can offer your adult patients

About VONVENDI

See what the first recombinant VWF can offer your patients

Learn more about the safety and efficacy

Efficacy & Safety

Learn more about the hemostatic efficacy and safety profile of VONVENDI

Three free doses of VONVENDI

VONVENDI Free Trial Program

Eligible patients can try VONVENDI with 3 free doses

Learn about dosing rVWF

Dosing & Administration

Dose according to your patient's individual need

Find information to help you and your adult patients manage VWD treatment

Clinician Resources

Find information to help you and your patients manage VWD treatment